Letrozole is sometimes prescribed off-label to induce ovulation in women with polycystic ovary syndrome. Clinical evidence suggests it can be as effective as traditional agents, but treatment should be supervised by a fertility specialist.
Take the missed tablet as soon as you remember on the same day. Do not take two tablets on the following day to compensate.
Letrozole may cause a modest increase in LDL cholesterol. Regular lipid monitoring is advisable, especially for patients with existing cardiovascular risk factors.
No specific food interactions are known. The tablet can be taken with or without meals, but maintain a balanced diet to support overall health.
For adjuvant treatment of post-menopausal breast cancer, therapy is commonly continued for up to five years, as directed by the oncology team.
Yes, but keep the medication in its original packaging with the prescription label. Carry a copy of the prescription in case customs officials request documentation.
Watch for yellowing of the skin or eyes, dark urine, severe abdominal pain, or unexplained fatigue. Seek urgent medical care if these symptoms appear.
Concurrent estrogen-containing treatments can negate the effect of letrozole and are not recommended. Discuss any hormonal supplements with your doctor.
Both drugs lower estrogen, but letrozole is often considered slightly more potent on a per-milligram basis. Choice of agent depends on individual tolerance, side-effect profile, and physician preference.
Because estrogen reduction can accelerate bone loss, baseline and periodic bone density scans are recommended. Calcium and vitamin D supplementation, along with weight-bearing exercise, may help mitigate this risk.
Femara contains letrozole as its active component. It is classified under women’s health and oncology support, primarily used as an aromatase inhibitor in hormone-responsive breast cancer. The medication is available as a 2.5 mg oral pill and is prescription-only (Rx) in the United Kingdom. Letrozole is marketed by Novartis under the brand name Femara and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Letrozole belongs to the aromatase inhibitor class. Aromatase is an enzyme that converts androgens into estrogen; by blocking this enzyme, letrozole markedly reduces circulating estrogen levels. Lower estrogen deprives estrogen-receptor-positive breast cancer cells of a growth stimulus, slowing tumor progression. The drug is absorbed rapidly after oral administration, reaching peak plasma concentrations within 2 hours. It is metabolised mainly by the liver (CYP3A4, CYP2A6) and eliminated in urine and feces with a half-life of about 2 days.
Femara is indicated for adult women who have completed menopause, either naturally or surgically, because the drug’s mechanism relies on the absence of ovarian estrogen production.
Letrozole is sometimes used off-label to stimulate ovulation in women with polycystic ovary syndrome (PCOS). Small-scale clinical studies have shown comparable pregnancy rates to clomiphene citrate, and the practice is reflected in some fertility guidelines. Off-label use requires medical supervision and individualized risk assessment.
These effects are generally mild and may improve with continued therapy or symptom-specific management.
This article provides educational information about Femara and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
